Cenix signs RNAi research agreement with SYGNIS
News Nov 17, 2011
Under the research agreement’s first assignment to advance the SYGNIS KIBRA project, Cenix will apply its long-standing expertise in combining high content screening with gene silencing analyses in cultured human cells, to establish and optimize multi-parametric microscopy-based assays using the Definiens XD image analysis system. Using such assays, Cenix will conduct target validation to prioritize novel therapeutic drug target candidates, thereby accelerating and enriching the SYGNIS drug development pipeline.
“We are delighted to enter into this new relationship with SYGNIS,” noted Dr. Christophe Echeverri, CEO/CSO of Cenix. “This project, and the many others like it now ongoing here and throughout the industry, continue to confirm the unparalleled power of RNAi-based experimentation for not only discovering but also validating and de-risking new candidate drug targets”.
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE